Air quality is the worst in WHO Eastern Mediterranean and Southeast Asia regions
MONDAY, April 4, 2022 (HealthDay News) — Almost no one in the world is breathing clean, healthy air, according to a new World Health Organization report, which issued a call for reducing the use of fossil fuels.
Air quality is the worst in the WHO Eastern Mediterranean and Southeast Asia regions, but 99 percent of the global population breathes air that exceeds air quality limits and contains disease-causing particles. Air quality is also especially poor in Africa.
“After surviving a pandemic, it is unacceptable to still have 7 million preventable deaths and countless preventable lost years of good health due to air pollution,” Maria Neira, M.D., head of the WHO Department of Environment, Climate Change, and Health, said in a news release from the United Nations health agency. “Yet too many investments are still being sunk into a polluted environment, rather than in clean, healthy air.”
The WHO database included PMâ‚‚.â‚…, PMâ‚â‚€ (particulate matter 2.5 and 10 micrometers small) and now ground measurements of nitrogen dioxide, the latter of which is generated through burning of fuel and is common in urban areas. WHO found the highest concentrations in the Eastern Mediterranean region.
“Particulate matter, especially PMâ‚‚.â‚…, is capable of penetrating deep into the lungs and entering the bloodstream, causing cardiovascular, cerebrovascular (stroke) and respiratory impacts,” according to the WHO. “There is emerging evidence that particulate matter impacts other organs and causes other diseases as well.”
Higher Short-Term Exposure to Pollen Linked to Lower FEV1 in COPD
Study Reveals Silicosis Rates Among Workers Fabricating Stone Countertops
Wildfires Now Top Source of Unhealthy Air for Pregnant Women in U.S.
Exposure to Air Pollutants Linked to Increased RA Disease Activity
Distinct Characteristics ID"d for Patients With Rheumatoid Conditions, Opioid Use Disorder
Timing of JAK Initiation, Shingles Vaccine Administration Can Affect Outcomes in RA
Bimekizumab Well Tolerated, Efficacious Over Three Years in Axial Spondyloarthritis